scholarly journals Palliative Embolization in Recurrent Nodal Bleeding in Nasopharyngeal Cancer: Case Report and Review of Literature

2020 ◽  
Vol 6 (2) ◽  
pp. 16-18
Author(s):  
Mohammed A. Naseer ◽  
◽  
Sharif A. W. Al Aryadh ◽  
Ravi M. Pedapenki ◽  
◽  
...  

Arterial embolization is used as one of the palliative procedure in the control of bleeding. We have demonstrated this procedure to be effective in the control of the bleeding in various malignancies in our center. This is our first case report in a teenaged nasopharyngeal cancer patient who had exhausted all his treatment as he had progressive disease and recurrent bleeding episodes from the recurrent neck nodal mass. This was controlled well with arterial embolization with no significant side effects.

2015 ◽  
Vol 13 (3) ◽  
pp. 417-419 ◽  
Author(s):  
Dani Ejzenberg ◽  
Lucienne Pereira Del Grossi Neusquen ◽  
Daniel Lorber Rolnik ◽  
Adriana Chebar Lozinsky ◽  
José Roberto Morales Piato

The coumadin-induced skin necrosis is rare and occurs more frequently in the breasts, thighs and buttocks. We describe the first case of coumadin necrosis of the breast in Brazil in a 62-year-old patient.


2015 ◽  
Vol 30 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Aisha Al-Sinani ◽  
Waad-Allah Mula-Abed ◽  
Manal Al-Kindi ◽  
Ghariba Al-Kusaibi ◽  
Hanan Al-Azkawi ◽  
...  

Breast Care ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. 424-426 ◽  
Author(s):  
Arpine Gevorgyan ◽  
Giacomo Bregni ◽  
Giulia Galli ◽  
Elisa Zanardi ◽  
Filippo de Braud ◽  
...  

Background: Neuroendocrine carcinoma is an uncommon histology for breast cancer. Case Report: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.


2013 ◽  
Vol 45 (S1) ◽  
pp. 22-24 ◽  
Author(s):  
Salvatore Lauro ◽  
Riccardo Righini ◽  
Concetta Elisa Onesti ◽  
Eugenio Pucci ◽  
Alessandra Bramini ◽  
...  

2014 ◽  
Vol 8 (3-4) ◽  
pp. 276 ◽  
Author(s):  
Kamaljot Singh Kaler ◽  
Rebekah Rittberg ◽  
Darrel Edmond Drachenberg

Renal angiomyolipoma (AML) is predominantly a non-aggressive benign tumour. Cases of more aggressive AMLs are present in the literature. We present 2 cases of aggressive AML behaviour. The first case is an AML with vascular extension in a young female and the second case is of AML found in regional lymph nodes in a female with a left renal AML and renal cell carcinoma.


2020 ◽  
Vol 77 (19) ◽  
pp. 1578-1584 ◽  
Author(s):  
Farah Khorassani ◽  
Frances Sousonis ◽  
Leonardo V Lopez

Abstract Purpose A case of hepatotoxicity likely due to use of risperidone and paliperidone is reported. Summary A 23-year-old man with schizophrenia was admitted to an inpatient psychiatric unit after an exacerbation of mental illness secondary to medication nonadherence. During 13 days of treatment with risperidone, the patient’s liver enzyme levels rose sharply, so antipsychotic therapy was switched to oral paliperidone. After a 5-day downward trend in liver enzyme levels, a dose of intramuscular paliperidone was administered to augment oral paliperidone therapy. After 10 days of paliperidone use, abnormally high liver enzyme levels were again noted; both oral and intramuscular paliperidone therapy were discontinued and haloperidol was initiated, with complete resolution of liver enzyme abnormalities within approximately 4 weeks. Scoring of this case using the algorithm of Naranjo et al indicated probable associations between risperidone use and hepatotoxicity (a score of 7) and paliperidone use and hepatotoxicity (a score of 8). To our knowledge, this is the first case report describing a patient who developed hepatotoxicity during risperidone use that did not remit with a switch to paliperidone therapy. Conclusion Findings of this case suggest that patients who develop hepatotoxicity with use of risperidone may also do so with paliperidone use; this, in turn, suggests that both risperidone and its metabolite are capable of causing hepatotoxicity. Patients who develop hepatotoxicity in response to risperidone or paliperidone therapy may benefit from treatment with an alternative antipsychotic with a different chemical structure.


2020 ◽  
Vol 142 ◽  
pp. 87-92
Author(s):  
Leonardo Tariciotti ◽  
Antonio Arrichiello ◽  
Giorgio Fiore ◽  
Giulio Bertani ◽  
Giorgio Conte ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document